Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;20(28):2097-2107.
doi: 10.1080/14796694.2024.2345043. Epub 2024 May 17.

Development of perioperative immune checkpoint inhibitor therapy for locally advanced esophageal squamous cell carcinoma

Toru Kadono  1   2 , Shun Yamamoto  1 , Ken Kato  1
Affiliations
Review

Development of perioperative immune checkpoint inhibitor therapy for locally advanced esophageal squamous cell carcinoma

Toru Kadono et al. Future Oncol. 2024.

Abstract

The standard preoperative treatment for resectable locally advanced esophageal squamous cell carcinoma (ESCC) is chemoradiotherapy in western countries (based on the CROSS trial) and triplet chemotherapy in Japan (based on the JCOG1109 trial). Postoperative nivolumab has recently been shown to improve disease-free survival in resectable locally advanced esophageal cancer after preoperative chemoradiotherapy in patients who had residual pathological disease, based on the CheckMate 577 trial. Furthermore, preoperative immune checkpoint inhibitor-containing treatments have also been developed. The JCOG1804E trial is presently evaluating the safety and efficacy of preoperative nivolumab-containing chemotherapy for resectable locally advanced ESCC. This review discusses the treatment of resectable locally advanced ESCC and future perspectives on perioperative immune checkpoint inhibitor-containing treatments.

Keywords: esophageal squamous cell carcinoma; immune checkpoint inhibitors; nivolumab; pembrolizumab; perioperative treatment; postoperative treatment; preoperative treatment.

Plain language summary

[Box: see text].

PubMed Disclaimer

Conflict of interest statement

T Kadono has no conflict of interest. S Yamamoto has received personal fees from ONO PHARMACEUTICAL and Bristol Myers Squibb, MSD, Taiho, M3, HOKUTO. K Kato has received research funds from Ono Pharmaceuticals, Bristol Myers Squibb, MSD, Merck Biopharma, Taiho Pharmaceutical, Bayer, AstraZeneca, Janssen, and Oncolys Biopharma; and honoraria from Ono Pharmaceuticals, Bristol Myers Squibb, MSD, and Taiho Pharmaceutical. The authors have no other competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript apart from those disclosed. This includes employment, consultancies, stock ownership or options and expert testimony.

Figures

Figure 1.
Figure 1.
Mechanism of action of immune checkpoint inhibitor therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sung H, Ferlay J, Siegel RL, et al. . Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. doi:10.3322/caac.21660 - DOI - PubMed
    1. Then EO, Lopez M, Saleem S, et al. . Esophageal cancer: an updated surveillance epidemiology and end results database analysis. World J Oncol. 2020;11(2):55–64. doi:10.14740/wjon1254 - DOI - PMC - PubMed
    1. Arnold M, Pandeya N, Byrnes G, et al. . Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 2015;16(1):36–46. doi:10.1016/S1470-2045(14)71123-4 - DOI - PMC - PubMed
    1. Kitagawa Y, Ishihara R, Ishikawa H, et al. . Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 1. Esophagus. 2023;20:343–372. doi:10.1007/s10388-023-00993-2 - DOI - PMC - PubMed
    1. Kitagawa Y, Ishihara R, Ishikawa H, et al. . Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 2. Esophagus. 2023;20:373–389. doi:10.1007/s10388-023-00994-1 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources